Adacyte Therapeutics

What Adacyte Therapeutics does

Adacyte Therapeutics is a Spain-based, privately held medical device company (ADACYTE THERAPEUTICS S.L., founded 2018, headquartered in Sant Cugat del Vallès near Barcelona) focused on the development and commercialization of Granulocyte-Monocyte Apheresis (GMA) therapy for autoimmune diseases. The company's core product, Adacolumn®, is a medical device consisting of a column filled with cellulose acetate beads that selectively adsorb activated granulocytes and monocytes expressing relevant surface molecules from peripheral blood, delivering a therapeutic effect without the immunosuppressive side effects typical of drug-based regimens.

The company's primary commercial focus is inflammatory bowel disease (ulcerative colitis and Crohn's disease), with additional therapeutic-area positioning in rheumatoid arthritis, ocular Behçet disease, pustular psoriasis, and systemic lupus erythematosus. The GMA platform is supported by a four-year clinical development program launched in 2020 in partnership with JIMRO (Japan Immunoresearch Laboratories, the manufacturer of Adacolumn®), spanning more than 1,000 patients, 150 researchers, and 80 university hospitals across Europe and the United States.

Adacyte generates revenue through hardware sales of the Adacolumn® device to hospitals and healthcare providers, distributed across Spain, France, Germany, and Sweden via regional distribution partners including Galenica, Innovamedica, and Boubyan. The go-to-market motion is enterprise field sales targeted at gastroenterologists, IBD specialists, rheumatologists, and hospital-based physicians, supported by a dedicated Healthcare Professional portal offering scientific publications, e-learning, an apheresis time calculator, slide kits, and event programming. The company is founder-led by Antoni Villaró, who serves as Founder & CEO; no external funding rounds, parent-company ownership, or acquisitions are disclosed in the available data.

Name

Adacyte Therapeutics

Legal name

ADACYTE THERAPEUTICS S.L.

Website

https://adacyte.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Adacyte Therapeutics is a Spain-based medical device company that develops and commercializes Adacolumn®, a granulocyte-monocyte apheresis (GMA) device for treating inflammatory bowel disease and other autoimmune conditions, sold to hospitals across Europe via regional distribution partners.

Ownership category

akta.pro rank

Product category

Apheresis Medical Devices

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Apheresis medical devices
• Granulocyte monocyte apheresis
• Inflammatory bowel disease treatment
• Autoimmune disease therapy
• Blood purification technology

Headquarters

HQ city

Sant Cugat Del Vallès

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of Adacolumn® medical devices and related apheresis products to hospitals and healthcare providers for treatment of IBD and autoimmune diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Adacyte Therapeutics develops and commercializes the Adacolumn® medical device, which delivers Granulocyte-Monocyte Apheresis (GMA) therapy for the treatment of inflammatory bowel disease (Crohn's disease, ulcerative colitis) and other autoimmune conditions including rheumatoid arthritis, ocular Behçet disease, pustular psoriasis, and systemic lupus erythematosus. GMA is an adsorptive blood purification technology that selectively removes activated pro-inflammatory granulocytes and monocytes from peripheral blood, providing a therapeutic effect without the side effects associated with immunosuppressive drugs. The company supports a multinational clinical development program in partnership with manufacturer JIMRO across Europe and the United States.

Product overview

Adacyte Therapeutics is a pharmaceutical/medical device company focused on the development and commercialization of therapeutic solutions for complex diseases. The company's primary product is Adacolumn®, a medical device that delivers Granulocyte-Monocyte Apheresis (GMA) therapy for the treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. The GMA therapeutic technology represents the core platform, with Adacolumn® being the branded medical device used to administer this treatment. The company operates a Healthcare Professional Area providing educational resources, clinical materials, and an Apheresis Time Calculator tool.

Differentiator

Problem solved

Functional benefit

Brands

• Adacolumn: Medical device for GMA (Granulocyte-Monocyte Apheresis) treatment in inflammatory bowel disease
• GMA

Products and services

• Adacolumn®

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and minor.

• JIMRO (Japan Immunoresearch Laboratories Co., Ltd)coreStrategic or Co-development Partner · 1 January 2020In 2020, Adacyte Therapeutics, in partnership with JIMRO (Japan Immunoresearch Laboratories Co., Ltd), launched an ambitious clinical development program for GMA. JIMRO manufactures the Adacolumn® product. Over the next four years, they are conducting clinical trials in Europe and the United States with over 1,000 patients, 150 researchers, and 80 university hospitals.
• EvinatureminorStrategic or Co-development PartnerEvinature provides clinically tested, natural solutions for inflammatory bowel disease. They offer innovative, natural, safe, and effective products backed by science. Adacyte features Evinature's CurQD® product in their educational materials.
• GalenicacoreChannel Partner/ Reseller/ DistributorGalenica is listed as a distribution partner helping Adacyte Therapeutics deliver innovative, effective, and comprehensive healthcare solutions to patients across Europe.
• InnovamedicacoreChannel Partner/ Reseller/ DistributorInnovamedica is listed as a commercial partner in the alliances section, helping Adacyte deliver healthcare solutions to patients across Europe.
• BoubyanminorChannel Partner/ Reseller/ DistributorBoubyan is listed as a commercial partner in the alliances section, contributing to Adacyte's European distribution network.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Others

• Galenica: Galenica is a Swiss pharmaceutical distributor and pharmacy operator listed as a core distribution partner for Adacyte. It is relevant as an ecosystem participant — the channel through which Adacolumn reaches European hospital customers — rather than a direct competitor.

Emerging players

• Kaneka Corporation: Kaneka has a medical division developing apheresis technologies (e.g., LIPOSORBER for LDL apheresis, and related immunoadsorption columns). It is comparable to Adacyte as a Japanese-origin developer of selective apheresis devices targeting immune-mediated diseases, with overlapping technology approach.

Broad incumbents

• Takeda Pharmaceutical: Takeda markets Entyvio (vedolizumab) for UC and Crohn's disease. It is a broad incumbent comparable to Adacyte because it is a leading IBD biologic competing for the same gastroenterologist prescribing decisions and patient populations that GMA also targets.
• Johnson & Johnson (Innovative Medicine): Johnson & Johnson markets Remicade, Stelara, and Tremfya for IBD and rheumatology. It is a broad incumbent comparable to Adacyte as a major biologic franchise owner serving the same gastroenterology and immunology patient population that Adacyte's GMA therapy addresses.
• AbbVie: AbbVie markets Humira, Skyrizi, and Rinvoq across IBD (UC and Crohn's) and rheumatology. It is a broad incumbent comparable to Adacyte because it addresses the same gastroenterologist and rheumatologist prescribers for the same autoimmune indications, but with systemically administered biologics rather than an apheresis device.
• Fresenius Kabi: Fresenius Kabi is a global healthcare company with a dedicated apheresis portfolio (e.g., Amicus, Com.Tec) used for therapeutic apheresis in autoimmune and hematologic conditions. Comparable to Adacyte because it operates in therapeutic apheresis, a much broader scale and product breadth, and serves overlapping hospital customers treating autoimmune diseases.

Direct peers

• Terumo BCT: Terumo BCT is one of the world's leading developers of blood component and therapeutic apheresis systems (Spectra Optia, Trima). It is a direct peer to Adacyte because both sell apheresis hardware and disposables to hospitals and blood centers for therapeutic indications, including immune-mediated conditions.
• Haemonetics: Haemonetics manufactures apheresis and blood processing devices (e.g., MCS+ cell separator). It is a direct peer to Adacyte as a provider of therapeutic apheresis technology sold into hospital and specialty clinic channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/channel/UCYxK7QAFw6zxa5mnSqPkB1Q
• Xx.com/adacyte
• LinkedInlinkedin.com/company/adacyte-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adacyte Therapeutics